Pollen Allergy - Pipeline Review, H1 2015

01:13 EDT 15 Apr 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Pollen Allergy - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-03-10. This 103-page report is available in PDF from $2000.

Pollen Allergy - Pipeline Review, H1 2015


Global Markets Direct’s, ‘Pollen Allergy - Pipeline Review, H1 2015’, provides an overview of the Pollen Allergy’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pollen Allergy and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- The report provides a snapshot of the global therapeutic landscape of Pollen Allergy
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Pollen Allergy and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Pollen Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Pollen Allergy pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of…

Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Pollen Allergy Overview 10
Therapeutics Development 11
Pipeline Products for Pollen Allergy - Overview 11
Pipeline Products for Pollen Allergy - Comparative Analysis 12
Pollen Allergy - Therapeutics under Development by Companies 13
Pollen Allergy - Therapeutics under Investigation by Universities/Institutes 15
Pollen Allergy - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Pollen Allergy - Products under Development by Companies 19
Pollen Allergy - Products under Investigation by Universities/Institutes 22
Pollen Allergy - Companies Involved in Therapeutics Development 23
ALK-Abello A/S 23
Allergopharma Joachim Ganzer KG 24
Allergy Therapeutics plc 25
Anergis SA 26
Biomay AG 27
BioTech Tools s.a. 28
Circassia Pharmaceuticals plc 29
HAL Allergy BV 30
Immunomic Therapeutics, Inc. 31
Japan Tobacco Inc. 32
Laboratorios LETI S.L. 33
REGiMMUNE Corporation 34
Roxall Medizin GmbH 35
Stallergenes S.A. 36
Pollen Allergy - Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Combination Products 38
Assessment by Target 39
Assessment by Route of Administration 40
Assessment by Molecule Type 42
Drug Profiles 44
ALK Birch Pollen Vaccine - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
AllerG - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Allergen Extract Of Phleum Pratense - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
AllerJ - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
AllerT - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
ASP-4070 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Avanz Phleum Pratense - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Birch-SPIRE - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
BM-31 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
BM-32 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
clustoid wiesenlieschgras - Drug Profile 58
Product Description…

For more information open Pollen Allergy - Pipeline Review, H1 2015.


Original Article: Pollen Allergy - Pipeline Review, H1 2015


More From BioPortfolio on "Pollen Allergy - Pipeline Review, H1 2015"

Quick Search


Relevant Topics

The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...